Alto Neuroscience Inc
NYSE:ANRO
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Alto Neuroscience Inc
NYSE:ANRO
|
523.2m USD |
Loading...
|
|
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
213.8B USD |
Loading...
|
|
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR |
Loading...
|
|
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD |
Loading...
|
|
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
103.6B ZAR |
Loading...
|
|
| US |
|
Schlumberger NV
NYSE:SLB
|
75.2B USD |
Loading...
|
|
| US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
58.4B USD |
Loading...
|
|
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
46.5B USD |
Loading...
|
|
| CH |
G
|
Galderma Group AG
SIX:GALD
|
35.3B CHF |
Loading...
|
|
| US |
|
Symbotic Inc
NASDAQ:SYM
|
37.2B USD |
Loading...
|
|
| ID |
|
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
563T IDR |
Loading...
|
Market Distribution
Other Profitability Ratios
Alto Neuroscience Inc
Glance View
Alto Neuroscience Inc is a US-based company operating in industry. The company is headquartered in Los Altos, California. The company went IPO on 2024-02-02. Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
